Dear customers,

we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal https://eifu.r-biopharm.com.

RIDASCREEN® IFX Monitoring

Verwendungszweck:RIDASCREEN® IFX Monitoring ist ein Enzymimmunoassay zum quantitativen Nachweis von Infliximab (IFX, Remicade®, anti-TNFα) und den Biosimilars Remsima®, Flixabi® und Inflectra® in [...]